Walkthrough: Design a GMP CRISPR Cell-Therapy Manufacturing Lab
This walkthrough scopes a greenfield 30,000 ft² (2,800 m²) Good Manufacturing Practice (GMP) cell-therapy facility producing autologous CAR-T and allogeneic CRISPR-edited hematopoietic stem cell (HSC) products. The site supports a Phase 2/3 program through commercial launch, 200-600 patient doses per year, with hot-cell-style segregated cleanroom suites for parallel autologous campaigns and a separate allogeneic master/working cell bank workflow. The architecture mirrors lessons from Vertex’s Boston + Stoughton expansion (Casgevy exa-cel manufacturing), Bluebird Bio’s Durham NC site (Lyfgenia, Skysona), Novartis Morris Plains NJ (Kymriah), Kite/Gilead El Segundo CA (Yescarta, Tecartus), Bristol-Myers Squibb Bothell WA (Abecma, Breyanzi), Cellares Bridgewater NJ (Cell Shuttle automated platform), Lonza Pearland TX, Cellular Origins (autologous robotic platform).
Reference programs: Vertex/CRISPR Therapeutics exa-cel (Casgevy — FDA Dec 2023, first CRISPR-edited therapy, sickle cell + β-thalassemia, $2.2M list price); Editas Medicine reni-cel (renizgamglogene autogedtemcel — Phase 1/2 for sickle cell + β-thal, paused Dec 2024 reorganization); Beam Therapeutics BEAM-101 (base-edited HSC, Phase 1/2 BEACON trial); Intellia NTLA-2001 (in vivo CRISPR for hereditary ATTR amyloidosis, Phase 3 MAGNITUDE 2024-2025); Caribou Biosciences CB-010 (allogeneic anti-CD19 CAR-T, lymphoma); Allogene ALLO-501A (allogeneic CAR-T with rituximab off-switch); Cellectis UCART22; Precision BioSciences PBCAR-19B (discontinued, pivoted in vivo).
1. Product spec
Two product classes share the facility:
| Parameter | Autologous CAR-T | Allogeneic CRISPR-edited HSC |
|---|---|---|
| Source material | Patient leukapheresis (60-200 mL, 1-10 × 10⁹ MNCs) | Donor mobilized peripheral blood (CD34+ selection from healthy donor) |
| Edit | Lentiviral transduction CD19 or BCMA CAR | CRISPR-Cas9 knockout of BCL11A erythroid enhancer (sickle/β-thal) or HLA + TRAC double KO (off-the-shelf CAR-T) |
| Expansion | T-cell activation + IL-2/IL-7/IL-15, G-Rex or rocking bag, 9-14 days | HSC expansion (UM171, SR1) 4-7 days, modest expansion 1.5-3× |
| Dose | 1-6 × 10⁸ CAR+ T cells | 3-30 × 10⁶ CD34+ cells/kg |
| Batch size | One patient = one batch | One donor = 10-100 doses |
| Cycle time | 10-16 days vein-to-vein | Master cell bank 30 days; per-dose pull 1-2 days |
| Annual throughput | 200-500 patients | 50-200 patients (each pulled from banked lot) |
| Release tests | ~25 assays, 7-14 day QC | ~30 assays, 14-21 day QC |
| Storage | Vapor-phase LN2 (-150°C) | Vapor-phase LN2, multi-site mirror |
The autologous flow is the bottleneck — every patient is a unique 10-16 day campaign tying up a Grade A/B suite. The allogeneic flow front-loads cleanroom time into bank generation, then becomes a fill-and-release exercise per dose.
2. Process flow
2.1 Autologous CAR-T
Patient leukapheresis (clinical site, day -2)
└─→ Cryopreserved or fresh ship to facility (day 0)
└─→ Thaw / wash / count (Grade C, biosafety cabinet — BSC)
└─→ T-cell isolation (CD4/CD8 magnetic selection)
└─→ Activation (anti-CD3/CD28 Dynabeads, TransAct)
└─→ Lentiviral transduction (CD19-CAR or BCMA-CAR vector)
└─→ Bead removal + transfer to expansion bag
└─→ Expansion in G-Rex 100M-CS or Xuri W25 (9-14 d)
└─→ Harvest, wash, formulate (CryoStor CS10)
└─→ Fill into cryobag (CryoMACS, Origen)
└─→ Controlled-rate freeze (CRF)
└─→ Vapor-phase LN2 storage
└─→ QC release (7-14 d)
└─→ Ship LN2 dry shipper to clinical site
2.2 Allogeneic CRISPR-edited HSC
Donor mobilization (G-CSF + plerixafor, clinical site)
└─→ Leukapheresis → cryopreserved HSC apheresis pack
└─→ Thaw + CD34+ enrichment (CliniMACS Prodigy CD34 protocol)
└─→ Electroporation with Cas9 RNP + sgRNA (MaxCyte GTx, ATx, or STx)
│ (BCL11A-enhancer guide for sickle/β-thal; TRAC + B2M for off-the-shelf CAR-T)
└─→ [If CAR product] Lentiviral or AAV6-HDR template transduction
└─→ Brief recovery culture (24-48 hr, IL-3/SCF/TPO/FLT3L)
└─→ Editing QC sample pull (Sanger + amplicon-NGS)
└─→ Wash + formulate (CryoStor CS5 or CS10)
└─→ Aliquot into multiple cryobags (10-100 doses per donor)
└─→ CRF + LN2 storage
└─→ Full QC release (14-21 d)
└─→ Per-patient pull + ship
3. Cleanroom architecture (ISO 14644 + EU GMP Annex 1 + 21 CFR 1271)
Cell-therapy GMP layers Annex 1 sterile-manufacturing requirements onto 21 CFR 1271 (HCT/P — Human Cell, Tissue, and Cellular and Tissue-Based Products) and FDA cellular + gene therapy guidance (notably the 2024 CMC for human gene therapy products draft and CBER Office of Therapeutic Products, OTP, formed 2023).
| Grade | Use | Implementation |
|---|---|---|
| Grade A | Critical aseptic open manipulation | ISO 5 in BSC class II A2 or isolator |
| Grade B | Background for legacy open Grade A | Avoided in new builds; replaced by isolator + closed processing |
| Grade C | General processing — CliniMACS, MaxCyte, G-Rex setup | ISO 7 cleanroom with cascade pressurization |
| Grade D | Material airlocks, gowning, secondary | ISO 8 |
| CNC | Warehouse, QC sample prep, offices | Controlled-not-classified |
3.1 Suite topology
Eight parallel autologous suites + two allogeneic suites + dedicated viral-vector receipt suite:
- 8 × autologous processing suites, ~25 m² each (4-5 BSCs, CliniMACS Prodigy, incubator, sealer, controlled-rate freezer)
- 2 × allogeneic suites, ~40 m² each (electroporation + enrichment + fill workstations)
- 1 × LV/AAV vector receipt + thaw room (BSL-2, separate HVAC return)
- 1 × cryostorage room (4-8 LN2 vapor freezers, MVE 1830 or Chart Industries XLC1840, 20-40k samples each)
- 1 × QC mycoplasma + sterility BSL-2 lab
- 1 × molecular QC lab (Sanger sequencer, qPCR, ddPCR, NGS prep)
- 1 × flow cytometry lab (BD FACSymphony A5 or Cytek Aurora 5L)
- Common: gowning corridors, material pass-through airlocks, waste airlock
Each autologous suite is a “campaign cell” — one patient enters, occupies the suite for 9-14 days, exits with frozen product. Cross-contamination control: physical segregation (no shared open Grade A air, dedicated personnel flow), color-coded disposable kits per patient, single-patient labeling discipline (barcode + chain-of-identity per FACT-JACIE + AABB standards).
3.2 HVAC
- Grade C: 20+ ACH, H14 HEPA terminal, +15 Pa above Grade D, 20-22°C, 35-55% RH
- BSC face velocity 0.4-0.5 m/s (NSF 49, ISO 14644-7)
- Dedicated AHU per suite cluster (autologous bank shares one, allogeneic separate, vector separate)
- 100% outside air or single-pass; no return air across product-contact zones for BSL-2 viral vectors
Pressure cascade and integrity: differential pressure logged continuously (Setra 264, Veris PXL); +/- 2 Pa alarms; recovery test (door open → close, return to setpoint in <30 s) part of qualification.
4. Cell processing equipment
4.1 CliniMACS Prodigy (Miltenyi Biotec)
The Prodigy is the workhorse closed-system automated processor for autologous CAR-T at sites worldwide — Novartis Kymriah was historically Prodigy-based at first decentralized sites.
- Single-use disposable TS520 tubing set, gamma-sterilized
- Onboard centrifuge, peristaltic pumps, magnetic separation column, incubator (37°C, 5% CO2)
- Programmable activities: CD4/CD8 selection, T-cell activation, transduction, expansion, harvest, formulation
- Process time per patient: 8-12 d in-instrument, hands-off after setup
- Unit price: $200-250k; disposable kit $2-4k per patient
- Throughput per instrument: ~25-40 patients/yr
Per 8 autologous suites: 8-12 Prodigy units. CapEx ~$2-3M.
4.2 MaxCyte electroporation (STX, GTx, ATx, VLx)
MaxCyte’s Flow Electroporation platform delivers Cas9 RNP into HSC, T cells, or NK cells at clinical scale. Vertex Casgevy uses MaxCyte under license + commercial supply agreement (announced 2017, expanded 2022).
- STx: research/clinical bench, 5 × 10⁹ cells per run
- GTx: GMP-grade, 200 mL/run, 1 × 10¹⁰ cells
- ATx: lower throughput clinical
- VLx (Very Large): up to 200 × 10⁹ cells, full allogeneic scale, ramped 2023-2024
For allogeneic CRISPR-HSC: 2 × GTx + 1 × VLx. CapEx ~$1.5M. Disposable processing assembly (PA) $3-5k per run.
4.3 Bioreactors / expansion
| Platform | Vendor | Use | Capacity |
|---|---|---|---|
| G-Rex (Gas-permeable Rapid Expansion) | Wilson Wolf | T cell, NK, TIL static expansion | G-Rex 100M-CS 1L, G-Rex 500M-CS 5L |
| Xuri Cell Expansion W25 | Cytiva | Rocking-bag T-cell expansion | 2-25 L working volume |
| Cocoon | Lonza | Fully closed automated, autologous | 60-180 mL product, ~25 patients/yr/unit |
| Quantum Cell Expansion | Terumo BCT | Hollow-fiber, MSC + T cell | 2.1 m² hollow fiber |
| Cell Shuttle | Cellares | Walk-up multi-patient automated platform | 6-10 simultaneous parallel autologous |
For this facility: G-Rex 500M-CS for autologous (low-cost, scalable per-patient), Xuri W25 backup for higher-cell-dose targets. Cocoon evaluated for late-stage automation (reduces operator interventions). Cell Shuttle is the strategic 2027-2028 capacity upgrade — Cellares signed deals with BMS, Cabaletta, Poseida 2023-2024.
4.4 Controlled-rate freezing + cryostorage
- Cryogenic controlled-rate freezer: Asymptote VIA Freeze (Cytiva), Planer Kryo 560 series, Custom BioGenic Systems CryoMed
- Typical cooling profile for cell therapy: 1-2°C/min through ice nucleation point, then 5-10°C/min to -80°C
- Transfer to vapor-phase LN2 within 4 hr of freeze
- LN2 vapor freezer: MVE 1830 (Chart Industries), Cryotherm Apollo 1500, Biocision CoolBox
- Inventory management: Brooks Life Sciences SmartFreezer + LIMS link (LabVantage, STARLIMS, Benchling LIMS)
5. CRISPR reagent supply
5.1 Cas9 protein
GMP Cas9 protein (SpCas9 NLS, typically tagged with HA or 6xHis purification handle):
- Aldevron (now part of Danaher) Cas9-2NLS — historical Vertex Casgevy supplier
- IDT (Integrated DNA Technologies) Alt-R S.p. HiFi Cas9 V3 + GMP equivalent (acquired by Danaher 2018)
- ThermoFisher TrueCut Cas9 GMP
- New England Biolabs EnGen Cas9 GMP
Specification: ≥95% purity by SEC-HPLC, endotoxin <0.1 EU/μg, BacMam/E. coli host residual <10 ppm, activity ≥10 units/μg by in vitro cleavage assay.
5.2 sgRNA / gRNA
Synthetic chemically modified single guide RNAs with 2’-O-methyl + phosphorothioate end protection:
- IDT Alt-R GMP-grade sgRNA (Coralville IA)
- Synthego CRISPRevolution GMP (Redwood City CA, manufacturing scale 2-50 g)
- Agilent Custom GMP sgRNA (acquired Lasergen 2018)
- TriLink BioTechnologies (San Diego CA)
Per Casgevy: ~1.5 mg sgRNA per dose; at $50-200/mg GMP-grade, sgRNA is a meaningful cost line ($75-300 per dose) but minor next to viral vector.
5.3 Viral vector (for CAR-T component)
Lentiviral vector (LV) production is the historical cost + capacity bottleneck for CAR-T:
- Self-inactivating (SIN) third-generation lentivirus (pseudotyped VSV-G typical, or measles H/F for targeted)
- CMO supply: Lonza Houston, Oxford Biomedica, ProBioGen, Charles River Memphis (acquired Cognate 2021), AGC Biologics Boulder, Catalent (acquired Paragon 2019, then Bloomington bioservices), Forge Biologics (acquired Ajinomoto 2023)
- In-house: Vertex Lexington MA + Stoughton, Bluebird Durham, Novartis Mensa Switzerland + Stein, Kite/Gilead El Segundo, BMS Bothell
AAV6 for HDR-template delivery (gene-correction sickle-cell, e.g. CRISPR Therapeutics + Vertex collaboration on exa-cel evolution):
- Sf9/baculovirus production: Catalent (Paragon), Forge Biologics, ProBioGen
- HEK293-triple transfection: ThermoFisher Patheon Lexington, Lonza Pearland TX
For our facility: 100% outsourced viral vector with secure long-term supply contract (typical Vertex-style 3-5 yr forward contracts, $200M-1B over term).
LV cost: $10-50k per patient dose at clinical scale, $3-20k at commercial scale (still 20-40% of COGS).
6. QC release testing
A cell therapy dose must pass 20-30 separate release assays before infusion. The QC backbone consumes 7-21 days of cycle time and is itself a major resource:
6.1 Sterility (USP <71> / Ph. Eur. 2.6.1 / 21 CFR 610.12)
- Compendial 14-day broth (FTM + SCDM) is incompatible with 10-16 day cell-therapy vein-to-vein cycle
- Rapid microbial methods (RMM): BacT/ALERT 3D (bioMérieux) — 7-day readout, broadly accepted under FDA 2024 cell-therapy guidance
- Bactec FX (BD): similar 5-7 day
- Sterility testing on day +1 sample (interim) + final product sample (concurrent with infusion)
6.2 Mycoplasma (USP <63> / 21 CFR 610.30)
- Compendial 28-day culture is impossible
- PCR-based rapid mycoplasma: Roche MycoTOOL, Charles River Mycoplasma SOLO, Lonza MycoAlert Plus
- Validated as equivalent under USP <1227>; required suite per ICH Q5A
- 24-48 hour turnaround
6.3 Endotoxin (USP <85>)
- LAL kinetic chromogenic (Charles River Endosafe-PTS, Lonza Kinetic-QCL)
- Or rFC (recombinant Factor C, Lonza PyroGene) — animal-free, USP <85> 2025 revision
- Spec ≤5 EU/mL for cell therapy (looser than parenteral biologics due to dose volume)
6.4 CRISPR edit quality
Editing efficiency + off-target characterization is the cell-therapy-unique QC layer:
- Sanger sequencing + TIDE / ICE deconvolution (Synthego ICE, Desktop Genetics TIDE) — % editing at target site
- Amplicon NGS — Illumina MiSeq or NextSeq 1000, deep sequencing target + top off-targets, indel spectrum quantification, 0.1% sensitivity
- GUIDE-seq / CIRCLE-seq / DISCOVER-seq / CHANGE-seq — unbiased off-target discovery (typically done at development, not lot release, but validates panel)
- Translocation detection — UDiTaS, droplet digital PCR for known chromosomal rearrangements (TRAC-B2M, TRAC-PD1 translocations in multi-edit CAR-T)
- Karyotype + CNV — G-banded karyotype 20-cell analysis, or low-pass whole-genome sequencing for CNV
- Acceptance criteria typical: ≥80% on-target editing, <0.1% individual off-target sites, no translocations >0.05% allele frequency
6.5 Vector copy number (VCN) and integration site analysis (for LV-CAR)
- ddPCR for VCN per cell (Bio-Rad QX600, ThermoFisher Absolute Q): spec typically <5 copies/cell to limit insertional risk
- Integration site analysis (LAM-PCR + NGS, or LiVE-Seq) for clonal expansion monitoring — required pre/post-2014 X-SCID-like adverse events (Bluebird bb305 reactivation 2019)
- Replication-competent lentivirus (RCL) test — co-culture with C8166 + RT-PCR endpoint, 21-day; required at every dose
6.6 Identity, potency, purity
- Identity — flow cytometry: CAR detection by anti-CAR scFv reagent, CD3/CD4/CD8/CD45 panel
- Potency — IFN-γ ELISA after target cell co-culture (CD19+ for CD19-CAR), CD107a degranulation; cytotoxicity assay (xCELLigence, IncuCyte) — surrogate or actual cell-kill
- Purity — % CD3+ T cells, % CD34+ HSC, residual feeder / non-target cell %
- Viability — 7-AAD or trypan blue exclusion + AOPI (acridine orange / propidium iodide on Cellaca MX, NucleoCounter NC-200/NC-202)
- Cell count + dose — automated counter (NucleoCounter, Cellaca, Countess) per dose calculation
6.7 Real-time release (RTRT) ambitions
The 7-14 day QC bottleneck is a major operational pain. RTRT under ICH Q8/9/10/11 + FDA 2024 cell-therapy CMC guidance permits PAT-driven release on validated in-process parameters — temperature, pH, glucose, lactate, oxygen, online flow cytometry (Cytek Aurora CS or Sartorius BioPAT FlowPath), inline Raman. Vertex + Novartis + BMS publicly piloted RTRT 2023-2025; full RTRT deployment 2026-2028.
7. Chain of identity + chain of custody (COI / COC)
Autologous cell therapy is uniquely error-intolerant: one mix-up = patient death and full FDA inspection. Layered identity controls:
- Apheresis pack label — barcode at clinical site, scanned and verified at facility receipt
- Vein-to-vein tracking — every transfer, every container, every QC sample logged in an electronic chain-of-identity system: Vineti (acquired by KineticPro 2023), TrakCel, TraceLink, SAP Advanced Therapy, Pluto (Vertex internal)
- 2-of-2 verification — two operators sign every patient-specific action
- Final product label — barcoded, contains patient-specific date-of-birth + medical record number cross-check
- Cold-chain integrity — LN2 dry shipper with continuous temperature logging (Cryoport, World Courier, Quick International, FedEx LifeScience)
FACT-JACIE (Foundation for the Accreditation of Cellular Therapy + Joint Accreditation Committee ISCT-EBMT) standards 8th edition (2023) require electronic COI; AABB Cellular Therapy Standards 11th edition codifies similar.
8. Facility utilities
8.1 Water + gas
- WFI (Water for Injection) — required for final formulation (CryoStor matrix), wash buffers, vehicle. Multi-effect still or membrane WFI (post-2017 Ph. Eur.); 200-500 L/d demand for this scale, much smaller than fill-finish
- PW (Purified Water) — equipment rinse, cleanroom mopping; ~1,000-2,000 L/d
- CO2 — incubators (5% in air for cell culture); medical grade, dual-cylinder manifold + auto-switchover
- N2 — LN2 (storage), gaseous N2 (overlay during cryomedium prep)
- LN2 — bulk tank 10,000-30,000 L on slab, weekly tanker fill (Air Liquide, Linde, Air Products, Praxair-Linde)
8.2 Power + UPS
- 1.5-3 MVA service from utility, 480V/277V industrial
- UPS coverage of all incubators + freezers + HVAC + LN2 level monitoring + LIMS + cleanroom lights: 30-60 min battery + diesel backup generator (Caterpillar C32, Cummins QSK60, Kohler KD3500)
- Tier III data-center-style redundancy for chain-of-identity LIMS
8.3 Environmental monitoring
Continuous monitoring + viable + non-viable particle sampling per Annex 1:
- Particle counters: Lighthouse Solair 3100+, TSI AeroTrak 9510, Particle Measuring Systems Lasair III — Grade A (≥0.5 μm) continuously sampled during operation
- Microbial samplers: SAS Super 100 (VWR), MAS-100 Iso NT, Climet Microbial Air Sampler — 1 m³ active sampling per Annex 1
- Settle plates + contact plates (Rodac, USP <797>) — passive monitoring
- Personnel monitoring: glove prints after every critical intervention
LIMS-integrated EMS (Environmental Monitoring System): Veeva Vault QMS, MasterControl, Honeywell OneWireless EMS, Vaisala viewLinc, Ellab EM-Suite.
9. Regulatory framework
| Regulation | Scope | Applies to |
|---|---|---|
| 21 CFR 1271 | HCT/P registration + screening + testing | Cell-source qualification |
| 21 CFR 210/211 | cGMP for finished pharmaceuticals | Drug-product manufacturing |
| 21 CFR 600 | Biologics general | License/BLA + standards |
| 21 CFR 312 | IND | Investigational stage |
| 21 CFR 1271.150(c)(1) | Same surgical procedure exception | Not applicable for engineered products |
| FDA CMC guidance for cell + gene therapy (2024 draft) | CMC product specifications | Phase 3 + BLA |
| FDA guidance on human gene therapy products incorporating CRISPR (Jan 2024) | Off-target + on-target genome editing characterization | All CRISPR-edited cell therapies |
| EU GMP Annex 1 (Aug 2023) | Sterile manufacturing | Aseptic processing, isolators |
| EU GMP Annex 2A (May 2024) | ATMPs (Advanced Therapy Medicinal Products) | EU-specific cell + gene therapy GMP |
| EMA Reflection paper on off-target genome editing | EU off-target characterization | EU CRISPR therapies |
| ICH Q5A(R2) (2023) | Viral safety for biotechnological products | LV/AAV + cell substrates |
| ICH Q5D | Cell substrates | Master + working cell banks |
| ICH Q8/Q9/Q10/Q11/Q12 | Pharmaceutical quality | Cross-cutting QbD |
| FACT-JACIE 8th ed | Cellular therapy accreditation | Clinical + manufacturing |
| AABB Cellular Therapy Standards 11th ed | Cellular therapy donor + product | US blood-bank tradition |
| ISBT 128 | Labeling standard | Cell therapy products |
Pre-Approval Inspection (PAI) by FDA + EMA + PMDA before commercial supply; cell therapy PAIs have historically been notoriously detailed — 5-15 day on-site, focus on chain-of-identity, environmental monitoring trend, batch-record integrity.
10. Cost build-up
10.1 CapEx (greenfield 30k ft²)
| Line item | Cost |
|---|---|
| Shell + core building, 30k ft² industrial | $15-30M |
| Cleanroom fit-out (Grade C + D, HVAC, walls, ceilings) | $25-50M |
| Process equipment (Prodigy ×10, MaxCyte ×3, Xuri ×5, G-Rex inventory, CRFs ×6, LN2 freezers ×8) | $10-15M |
| QC equipment (BacT/ALERT, ddPCR, NGS, flow cytometers, HPLC) | $5-10M |
| LIMS + ERP + COI software + integration | $3-8M |
| Validation + commissioning + qualification (CQV) | $8-15M |
| BLA-readiness consulting + regulatory submissions | $3-7M |
| Working capital + initial inventory + raw material | $10-20M |
| Total | $80-200M |
Reference: Vertex Stoughton MA exa-cel facility ~$300M; Bluebird Durham ~$150M; Cellares Bridgewater + Sequel Med Tech automation buildout $200M+ over 5 yr.
10.2 OpEx per dose
| Cost driver | Per-dose cost |
|---|---|
| Viral vector (LV or AAV6) | $10,000-30,000 |
| CRISPR reagents (Cas9 + sgRNA) | $500-2,000 |
| CliniMACS Prodigy disposable | $3,000-5,000 |
| MaxCyte processing assembly | $3,000-5,000 |
| Culture media + cytokines + bags + tubing | $5,000-15,000 |
| QC reagents + outsourced tests | $10,000-25,000 |
| Direct labor (8-12 FTEs × 12 days) | $15,000-30,000 |
| Cleanroom + facility overhead allocation | $10,000-25,000 |
| Cold-chain shipping + COI | $3,000-8,000 |
| Cryostorage + LN2 + insurance | $2,000-5,000 |
| QA / batch-record review / release | $5,000-15,000 |
| Total per-dose COGS | $80,000-300,000 |
Casgevy + Lyfgenia + Skysona list prices $2.2-3.1M reflect this COGS plus development amortization + payer-negotiated rebates. Real net price after Medicaid + 340B + outcomes-based contracts: $1.5-2.5M.
10.3 Headcount
- Manufacturing operators: 40-80 FTE (3 shifts × 8 suites × 2-3 operators/suite + relief)
- QC: 30-50 FTE (sterility, micro, molecular, flow, release)
- QA: 20-40 FTE (batch-record review, deviation, change control, supplier qual)
- Facilities + utilities + EMS: 10-15 FTE
- Supply chain + logistics + COI: 10-20 FTE
- Regulatory + technical services + validation: 10-15 FTE
- Management + finance + HR: 10-20 FTE
- Total: 130-240 FTE
Industry rule of thumb: 0.5-1.0 FTE per patient-dose-per-year throughput at autologous, much lower for allogeneic at steady state.
11. Schedule
| Phase | Duration | Notes |
|---|---|---|
| Site selection + design | 6-9 mo | Often colocated with academic medical center or biotech cluster — Boston/Cambridge, BayArea, RTP NC, Philadelphia, San Diego |
| Permitting + construction | 18-30 mo | Cleanroom shell up in 12-18 mo; fit-out in parallel |
| Equipment install + commissioning | 6-12 mo | Often overlaps last 6 mo of construction |
| IOQ + PQ (Installation, Operational, Performance Qualification) | 6-12 mo | Includes media-fill simulation × 3 successful + smoke studies + EMS performance |
| Engineering runs + process validation (PPQ ×3) | 6-12 mo | Three full process validation batches at commercial scale per ICH Q8/Q11 |
| BLA submission + PAI + approval | 12-18 mo | 6-month Priority Review possible for breakthrough designation |
| Total greenfield → commercial first dose | 5-7 years |
For a Phase 2/3 program already underway, retrofit + capacity expansion typically 18-30 months.
12. Adjacent
- design-pharma-fill-finish-line — sterile fill-finish for the cryobag formulation step
- design-fda-drug-approval-pipeline — BLA submission + clinical-trial framework
- design-hospital-mri-installation — clinical-site infrastructure where cells are infused
- genetics-and-genomics — CRISPR mechanism + off-target biology
- immunology-foundations — CAR-T + checkpoint biology
- cell-molecular-biology — cell-cycle + transduction biology
- intellectual-property-deep — CRISPR-Cas9 IP estate (Broad/Berkeley/Vienna patent estate, MaxCyte license)